Faculty

Institution

Unit

Venue

Christopher Amling, M.D., F.A.C.S

Professor of Urology School of Medicine John C Barry Chair of Urology

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Urology

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Department Of Urology

Division Of Pediatric Urology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Christopher Amling, M.d., F.a.c.s is currently serving as a Biostatistics Shared Resources Professor of Urology School of Medicine John C Barry Chair of Urology at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Christopher Amling, M.D., F.A.C.S

Oregon Health & Science University

Professor of Urology School of Medicine John C Barry Chair of Urology

You can click a keyword to filter the displayed items

urology prostate cancer oncology radical prostatectomy surgery search database cancer care surgical oncology cancer research prostatic disease genitourinary cancers neurology biochemical recurrence obesity cancer treatment health sciences cancer management cancer disparities metastasis cancer imaging cancer risk race urological research survival analysis cancer biology tumor biology benign prostatic hyperplasia urogynecology cancer prevention castration-resistant prostate cancer medicinal research androgen deprivation therapy vascular biology pharmacotherapy cancer discovery prognosis prostate-specific antigen clinical transplantation surgical pathology gastrointestinal surgery general surgery localized prostate cancer search database group jama oncology histopathology cancer screening reconstructive urology clinical evidence mri-guided radiation therapy image guidance overall survival biochemical failure cancer cells disease risk assessment cancer detection epidemiology of cancer urogenital radiology health disparities patient-reported outcomes prostate cancer outcomes androgen-deprivation therapy united states medical mycology clinical databases computed tomography health inequalities oncologic imaging prostate specific antigen skeletal-related events reproductive medicine race relations kidney transplantation voiding dysfunction risk factors treatment and prevention lymphoid neoplasia

Notable Scholarly Works

Notable Federal Grants

Collaborators

Does a Statin a Day Keep Prostate Cancer (Pc) Away?: Statin Use and Disease Progression in Patients Receiving Androgen Deprivation Therapy (Adt) After Radical Prostatectomy (Rp) in Search.. Journal of Clinical Oncology (2026)

surgical oncologyprostate cancerprostatic diseaseurologypharmacotherapycancer careoncology

Genomic and Molecular Associations With Preoperative Immune Checkpoint Inhibition in Patients With Stage III Clear Cell Renal Cell Carcinoma. Cancers (2026)

molecular associationskidney cancercancer immunotherapyimmunologyimmunotherapymolecular cancergenitourinary cancerscancer discoveryjama oncologycancer genomicsurologyimmune checkpoint inhibitors

Alternate Definitions of Adverse Pathology to Predict a Very High Risk of Metastasis in Men With Intermediate‐ and Low‐Risk Prostate Cancer. Cancer (2025)

Peris CastanedaPaige K. KuhlmannJaruda IthisuphalapLauren E. HowardZachary KlaassenLourdes Guerrios RiveraChristopher L. AmlingWilliam J. AronsonMatthew R. CooperbergChristopher J. KaneMartha K. TerrisStephen J. Freedland

epidemiologygenitourinary cancerscarcinogenesisadverse pathologycancer discoveryvascular biologyalternate definitionstumor biologyreal world evidenceprostatic diseasecancer researchlow-risk prostate cancercancer cellstumoral pathologyoncogeneshigh riskprostate cancerurologycancer carekey sitebiostatisticsoncology

Initial Biopsy Results of the Patrol Study: Prostate Screening for People With Inherited Risk of Developing Aggressive Prostate Cancer.. Journal of Clinical Oncology (2025)

Daniel LeeCaitlin OrrKara N. MaxwellAndrew AminiChristopher L. AmlingAileen J FengStephanie GoettlKristin FollmerGrace JunChenee HolcombShelley McCormickMargaret O'DeaMaxwell PooleLinda RodgersAlexandra SokolovaMaliha N TayebErika WolffKeyan SalariHeather H. ChengDaniel W. Lin

patrol studyepidemiologypathologysurgical oncologyurogynecologycancer discoveryaggressive prostate cancertumor biologycancer screeningprostate screeningcancer researchbiomarkersbenign prostatic hyperplasiagastrointestinal oncologyclinical investigationprostate cancercancer riskurologycancer carecohort studiesclinical epidemiologyinherited risk

Interim Analysis of the “Shutter Speed” Mri Model to Detect Clinically Significant Prostate Cancer.. Journal of Clinical Oncology (2025)

medical image computingradiation oncologymri-guided radiation therapymedical imagingprostate cancerradiologycancer imagingoncologic imagingnuclear medicineprostatic diseaseinterim analysisurologysignificant prostate cancercancer careoncologybiomedical imaging

Quantifying the Impact of Biochemical Recurrence After Radical Prostatectomy on Overall Mortality by Years of Life Lost: Results From the Search Database. European Urology Oncology (2025)

radiation oncologyprognosisprognostic evaluationradical prostatectomysurgical oncologygenitourinary cancersprostate cancerprostatic diseasebiochemical recurrencesearch databaseurologycancer careoncologymortality

Risks of Progression After Early Androgen Deprivation Therapy for Biochemical Recurrence After Radical Prostatectomy. The Journal of Urology (2025)

radiation oncologyendocrinologyendocrine-related cancersradical prostatectomysurgical oncologygenitourinary cancersprostate cancerprostatic diseasebiochemical recurrenceurologycancer careoncology

Contemporary Risk of Biochemical Recurrence After Radical Prostatectomy in the Active Surveillance Era. Urologic Oncology Seminars and Original Investigations (2024)

Sanjay DasMichael LuuMartha TerrisZachary KlaassenChristopher J. KaneChristopher AmlingMatthew CooperbergLourdes Guerrios RiveraWilliam AronsonStephen J. FreedlandTimothy J. Daskivich

contemporary riskepidemiologyactive surveillance eraradical prostatectomyprostate cancercancer researchcancer riskurologyhealth sciencesbiochemical recurrence

Do Hispanic Puerto Rican Men Have Worse Outcomes After Radical Prostatectomy? Results From Search. Cancer Medicine (2024)

Lourdes Guerrios‐RiveraJessica L. JanesAmanda M. De HoedtZachary KlaassenMartha K. TerrisMatthew R. CooperbergChristopher L. AmlingChristopher J. KaneWilliam J. AronsonJay H. FowkeStephen J. Freedland

radical prostatectomysurgeryprostate canceroutcomes researchurologycancer treatmentoncology

Prototype Description and Ex Vivo Evaluation of a System for Combined Endorectal Magnetic Resonance Imaging and In-Bore Biopsy of the Prostate. Journal of Computer Assisted Tomography (2024)

medical image computingprototype descriptionmedical imagingmagnetic resonance imagingprostate cancerradiologycancer imagingimage guidanceex vivo evaluationurologyin-bore biopsybiomedical imagingurogenital radiology

1
2
3
4
5
39
10 / page

Christopher Amling, M.D., F.A.C.S

Professor of Urology School of Medicine John C Barry Chair of Urology

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Urology

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Department Of Urology

Division Of Pediatric Urology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Christopher Amling, M.d., F.a.c.s is currently serving as a Biostatistics Shared Resources Professor of Urology School of Medicine John C Barry Chair of Urology at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Christopher Amling, M.D., F.A.C.S

Oregon Health & Science University

Professor of Urology School of Medicine John C Barry Chair of Urology

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

surgical oncologyprostate cancerprostatic diseaseurologypharmacotherapycancer careoncology

Genomic and Molecular Associations With Preoperative Immune Checkpoint Inhibition in Patients With Stage III Clear Cell Renal Cell Carcinoma. Cancers (2026)

molecular associationskidney cancercancer immunotherapyimmunologyimmunotherapymolecular cancergenitourinary cancerscancer discoveryjama oncologycancer genomicsurologyimmune checkpoint inhibitors

Alternate Definitions of Adverse Pathology to Predict a Very High Risk of Metastasis in Men With Intermediate‐ and Low‐Risk Prostate Cancer. Cancer (2025)

Initial Biopsy Results of the Patrol Study: Prostate Screening for People With Inherited Risk of Developing Aggressive Prostate Cancer.. Journal of Clinical Oncology (2025)

Interim Analysis of the “Shutter Speed” Mri Model to Detect Clinically Significant Prostate Cancer.. Journal of Clinical Oncology (2025)

Quantifying the Impact of Biochemical Recurrence After Radical Prostatectomy on Overall Mortality by Years of Life Lost: Results From the Search Database. European Urology Oncology (2025)

Risks of Progression After Early Androgen Deprivation Therapy for Biochemical Recurrence After Radical Prostatectomy. The Journal of Urology (2025)

radiation oncologyendocrinologyendocrine-related cancersradical prostatectomysurgical oncologygenitourinary cancersprostate cancerprostatic diseasebiochemical recurrenceurologycancer careoncology

Contemporary Risk of Biochemical Recurrence After Radical Prostatectomy in the Active Surveillance Era. Urologic Oncology Seminars and Original Investigations (2024)

Sanjay DasMichael LuuMartha TerrisZachary KlaassenChristopher J. KaneChristopher AmlingMatthew CooperbergLourdes Guerrios RiveraWilliam AronsonStephen J. FreedlandTimothy J. Daskivich

contemporary riskepidemiologyactive surveillance eraradical prostatectomyprostate cancercancer researchcancer riskurologyhealth sciencesbiochemical recurrence

Do Hispanic Puerto Rican Men Have Worse Outcomes After Radical Prostatectomy? Results From Search. Cancer Medicine (2024)

radical prostatectomysurgeryprostate canceroutcomes researchurologycancer treatmentoncology

Prototype Description and Ex Vivo Evaluation of a System for Combined Endorectal Magnetic Resonance Imaging and In-Bore Biopsy of the Prostate. Journal of Computer Assisted Tomography (2024)

1
2
3
4
5
39
10 / page